Upstream Processing CDMOs
46 published
46 published CDMOs match Upstream Processing.
Locations in this set include United States, United Kingdom, China, Germany, India, and Japan.
Capabilities that show up most often in this set: Biologics (Other), Biologics (Monoclonal Antibodies), Gene Therapy, Vaccine, and AAV / Viral Vector Platform.
Matching companies
Sophia CDMOEuropean CDMO specializing in microbial and precision fermentation up to 40,000 L across two integrated sites (Pamplona, Spain and Basel, Switzerland), with core strengths in E. coli expression, animal health biologics, probiotics, and complex CMC programs requiring scale-up discipline and impurity control.
Syngene InternationalInnovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.
ValidogenVALIDOGEN provides Pichia pastoris strain development and fermentation process development services for recombinant protein manufacturing, with proven scale-up to 200,000 L and titers up to 45 g/L.
WuXi BiologicsGlobal biologic CDMO offering end-to-end solutions from discovery to commercialization.
WuXi VaccinesGlobal CDMO specializing in end-to-end vaccine and prophylactic antibody development and manufacturing across mammalian, viral, and microbial platforms with GMP-certified facilities and over 550 million doses delivered.
Yapan BioYapan Bio provides integrated process development, characterization, and GMP manufacturing for vaccines, monoclonal antibodies, gene therapy, and viral vector-based biologics, with capabilities up to 1000L bioreactor scale and BSL-2+ containment.
Markdown mirror: /services/upstream-processing.md